New hope for gout sufferers who failed last resort treatment

NCT ID NCT07116746

First seen Dec 29, 2025 · Last updated May 25, 2026 · Updated 20 times

Summary

This study tests a new oral medication, AR882, taken with a standard gout drug (XOI) in 15 adults with uncontrolled gout who could not tolerate or stopped responding to uricase infusions. The goal is to lower uric acid levels below 6 mg/dL and shrink painful uric acid crystal deposits (tophi) over 6 months. Participants must have at least one visible tophus and meet kidney function requirements.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERURICEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Arthrosi Investigative Site (102)

    Miami, Florida, 33155, United States

  • Arthrosi Investigative Site (103)

    Duncansville, Pennsylvania, 16635, United States

  • Arthrosi Investigative Site (104)

    West Lake Hills, Texas, 78746, United States

  • Arthrosi Investigative Site (105)

    Margate, Florida, 33063, United States

  • Arthrosi Investigative Site (106)

    Jackson, Mississippi, 39202, United States

  • Arthrosi Investigative Site (107)

    Bellevue, Washington, 98004, United States

  • Arthrosi Investigative Site (108)

    Charlotte, North Carolina, 28202, United States

  • Arthrosi Investigative Site (109)

    Tampa, Florida, 33609, United States

Conditions

Explore the condition pages connected to this study.